论文部分内容阅读
目的研究Delta样配体4(Delta-like Ligand4,DLL4)在乳腺癌中的表达及临床意义。方法通过免疫组织化学染色及组织芯片方法检测122例乳腺浸润性导管癌和28例导管原位癌中DLL4的表达,结合临床病理学资料进行统计分析。结果 DLL4在乳腺导管原位癌、浸润性导管癌Ⅰ级、浸润性导管癌Ⅱ级、浸润性导管癌Ⅲ级中的表达率分别为21.4%、48.5%、75%、91.8%,其表达随分级的增高而增高,各组相比差异有统计学意义(P均<0.05),而且DLL4的表达与肿瘤大小、临床分期及淋巴结转移状态呈正相关(P均<0.05),与患者年龄、雌激素受体、孕激素受体及HER2表达情况无相关性(P均>0.05)。结论 DLL4的作用在乳腺癌演进晚期较早期强,可能与乳腺癌的发展及预后相关,可作为预测乳腺癌预后的重要参考指标及乳腺癌靶向治疗的新靶点。
Objective To study the expression of Delta-like Ligand4 (DLL4) in breast cancer and its clinical significance. Methods The expression of DLL4 in 122 cases of invasive ductal carcinoma of breast and 28 cases of ductal carcinoma in situ were detected by immunohistochemistry and tissue microarray. Statistical analysis was made based on the clinicopathological data. Results The expression rates of DLL4 in primary ductal carcinoma, grade Ⅰ invasive ductal carcinoma, grade Ⅱ invasive ductal carcinoma and grade Ⅲ invasive ductal carcinoma were 21.4%, 48.5%, 75% and 91.8% (P <0.05), and the expression of DLL4 was positively correlated with tumor size, clinical stage and lymph node metastasis (all P <0.05), but not with age, Hormone receptor, progesterone receptor and HER2 expression (P> 0.05). Conclusion The role of DLL4 is stronger in early stage of breast cancer evolution and may be related to the development and prognosis of breast cancer. It may be used as an important reference index to predict the prognosis of breast cancer and a new target of breast cancer targeted therapy.